Learn about the PRESIDIO Clinical Trial of KZR-616 for the Treatment of Polymyositis and Dermatomyositis
About Kezar, KZR-616, and PRESIDIO
Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live on Rare Disease Day 2020 and introduced Kezar, KZR-616, and the PRESIDIO Clinical Study.
In this video, Dr. Farmer discusses the science behind KZR-616, an investigational treatment for autoimmune diseases, and provides an overview of PRESIDIO, a phase 2 study of KZR-616 in Polymyositis and Dermatomyositis which is currently enrolling in trial sites across the U.S.
About Dr. MK Farmer, MD
Dr. Mary Katherine (MK) Farmer, MD received her medical training at the Medical College of Georgia, graduating in 2001. She completed her Internal Medicine training at the University of South Carolina (USC) from 2001-2004 where she first became interested in rheumatology. From 2004-2006 she worked as an inpatient hospitalist in Charleston, SC, and then on faculty at USC. She attended the University of North Carolina at Chapel Hill (UNC) from 2006-2009 for Rheumatology Fellowship and was invited to present her research on lupus nephritis and mycophenolate mofetil (CellCept®) at national and local conferences.
She was diagnosed with dermatomyositis in 2003 during residency and left clinical practice in 2010 to pursue a career in clinical research with her strong foundation in autoimmune diseases. She has worked with most of the major pharmaceutical companies and has worked on several medications that have been approved for different diseases.
She came to Kezar Life Sciences in mid-2019 to take a once-in-a-lifetime opportunity to run the myositis development program.
About Kezar Life Sciences
A sponsor of Myositis Support and Understanding (MSU)
Founded in 2015 and based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Kezar believes that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases.
Kezar is currently recruiting patients to participate in Phase 2 clinical trials. The diseases being studied in these trials are: lupus nephritis, dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia.